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Department of Medicine II, University of Freiburg, Hugstetter Strasse 55, D-79106 Freiburg, GermanyHepatocellular carcinoma (HCC) is one of the most common of tumour cells by inducing or boosting the existing tumour-spe-
malignancies worldwide with limited therapeutic options. Since
HCC has been shown to be immunogenic, T cell-based immuno-
therapy is considered a promising treatment. In this review, we
summarize current knowledge of T cell responses against
tumour-associated antigens, as well as the mechanisms underly-
ing the poor quality of these responses in patients with HCC.
Insights into these important aspects of HCC immunology are
crucial for the further development of novel immunotherapies.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.The need for immunotherapy
Hepatocellular carcinoma (HCC) is the third leading cause of can-
cer deaths worldwide with over 600,000 patients dying from this
disease annually [1]. Liver transplantation and tumour resection
have proven to be the most effective standard therapies and pro-
vide 5-year survival rates of 70% for patients within the Milan cri-
teria, i.e., single tumour 65 cm in size or up to three tumours
63 cm in size [2]. These rates reach 50% with radiofrequency
ablation and transarterial chemoembolization, which are the next
preferred lines of therapy. However, these therapeutic proce-
dures most often do not provide a complete cure, as half of the
treated patients experience tumour recurrence within 3 years. A
further major problem is that only 30–40% of patients are eligible
for the above-described treatments due to the fact that HCC fre-
quently remains undiagnosed until an advanced stage has been
reached. These patients have a median survival time ranging
from 3 to 16 months [3]. Thus, there is currently ongoing devel-
opment and testing of alternative drug-based therapies for HCC
that target tumour signalling pathways and vasculature. How-
ever, so far, the only drug that signiﬁcantly prolonged survival
(by nearly 3 months) in patients with advanced HCC is sorafenib,
a multi-targeted tyrosine kinase inhibitor [4].
In view of these facts, new strategies are required. Immuno-
therapy aims to provide a more efﬁcient and selective targetingJournal of Hepatology 20
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is based, for example, on the ﬁnding that patients with tumours
containing inﬁltrating, presumably tumour-speciﬁc effector T
cells, had a reduced risk of tumour recurrence following liver
transplantation [5]. Moreover, anti-CD3 and IL-2 stimulated
autologous T lymphocytes infused in HCC patients signiﬁcantly
improved post-surgical recurrence-free survival [6]. These data
imply a central role of T cells in modulating tumour progression
and provide strong justiﬁcation for T cell immunotherapy.TAA-directed T cell responses
A prerequisite for the successful development of T cell-based
immunotherapeutic approaches is the identiﬁcation and charac-
terization of immune responses to tumour-associated antigens
(TAAs). So far, six HCC-speciﬁc TAAs that are targeted by T cells
have been identiﬁed (summarized in Table 1).a-Fetoprotein (AFP)
AFP is expressed during foetal development but is transcription-
ally repressed shortly after birth. However, it is re-expressed in
the majority of HCC patients. Since it is a self-protein, it has been
argued that AFP-speciﬁc T cell responses are suppressed and thus
difﬁcult to activate. Nevertheless, AFP is currently the best stud-
ied and most promising target antigen for HCC immunotherapy.
In pioneering studies, the group of Butterﬁeld and Economou
identiﬁed an HLA-A2-restricted AFP-speciﬁc CD8 T cell epitope
and demonstrated its ability to generate CD8+ T cell responses
both in human lymphocyte cultures and in HLA-A2 transgenic
mice [7]. The authors further identiﬁed four dominant and 10
subdominant AFP-speciﬁc epitopes [8–10] (Table 1), all of which
induced low to moderate CD8+ T cell responses in PBMCs of HCC
patients [11,12]. We recently compared AFP-speciﬁc CD8+ T cell
responses in PBMCs with those in tumour-inﬁltrating lympho-
cytes (TILs) and surrounding non-tumour liver tissue by stimulat-
ing lymphocytes with 18-mer overlapping peptides spanning the
entire AFP protein [13] (Table 1). Interestingly, we found T cell
responses against several previously unidentiﬁed epitopes with-
out a clear immunodominance, indicating that more AFP-speciﬁc
epitopes exist and need to be identiﬁed. These results also indi-
cate that CD8+ T cells speciﬁc for the self-antigen AFP are present
in the normal T cell repertoire and are not centrally or peripher-
ally deleted.11 vol. 54 j 830–834
Table 1. TAAs triggering T cell responses in HCC patients.
Antigen Frequency of 
expression
CD8+ T cell responses T cell detection method Presenting 
HLA
Reference
AFP <80% 6/6 patients to dominant epitopes 
AFP137-145, AFP158-166 , AFP325-334
 and AFP542-550 
PFAotstneitap6/6 137-145, AFP158-166,
AFP325-334, AFP542-550 and
subdominant epitopes
24/40 patients to 18-mer 
peptides not comprising 
above-described 
epitopes
Ex vivo ELISPOT and tetramer 
staining on PBMCs 
ELISPOT on blood 
CD8+ T cells stimulated 
with epitopes for 3 weeks 
ELISPOT and intracellular 
cytokine staining (ICS) on  
blood and TIL CD8+ T cells 
non-specifically 
expanded for 2 weeks 
A0201
A0201
Diverse 
Butterfield, 2003
]21[
Liu, 2006
[11]
Thimme, 2008 
[13]
GPC3 <70% 11/22 patients to 
GPC144-152, GPC298-306 
Cytotoxicity assay on 
blood CD8+ T cells 
stimulated with epitope- 
-pulsed DCs for 2 weeks 
A2  
and  
A24 
Komori, 2006
[14]
NY-ESO-1 <50% 5/6 patients to  NY-ESO-1157-165
otstneitap82/01 NY-ESO-1157-165
6/10 patients to NY-ESO-1157-165 
with alanine substitution 
at position 165
ICS on PBMCs stimulated 
with epitope for 1 week 
ELISPOT and tetramer 
staining on blood CD8+
T cells stimulated with 
epitope for 2-3 weeks 
ICS on PBMCs 
stimulated with epitope 
for 2 weeks 
A2 
2A
A2
Korangy, 2004 
[16]
4002,gnahS
[17]
Gehring, 2009
[15]
SSX-2 <50% 3/6 patients to SSX-241-49
3/10 patients to  SSX-241-49
Tetramer staining on 
blood and TIL CD8+ T cells 
stimulated with  
epitope-pulsed DCs for 
3-4 weeks and then with 
PHA prior to analysis 
ICS same as for NY-ESO-1
A2 
A2
Bricard, 2005
[18]
Gehring, 2009 
[15]
MAGE-A <80% 1/6 patients to MAGE-1161-169 
1/6 patients to MAGE-1168-176
3/6 patients to  MAGE-10254-262
Tetramer staining on 
PBMCs and TILs stimulated 
with epitopes for 2 weeks 
Tetramer staining same  
as for SSX-2
A1 and A2 
A2
Zerbini, 2004
[19]
Bricard, 2005
[18]
TERT <80% 44/72 patients to TERT1088-1096, 
TERT845-853, TERT 167-175,
TERT461-469, TERT324-332,
TERT637-645
Ex vivo ELISPOT on 
PBMCs and TILs  
A24 Mizukoshi, 2006
[20]
JOURNAL OF HEPATOLOGYGlypican-3 (GPC3)
GPC3 is a foetal oncoprotein. It belongs to a family of heparan sul-
phate proteoglycans that can bind growth factors (e.g., Wnt,
FGF1/2, and VEGF) and thereby promote tumour growth. GPC3
was recently found to be over-expressed in HCC and is considered
a promising target antigen. Two HLA-A2- and HLA-24-restricted
CD8 T cell epitopes of GPC3 have been mapped in mice andJournal of Hepatology 201shown to elicit T cell responses in HCC patients after long-term
in vitro stimulation of PBMCs [14] (Table 1).
NY-ESO-1
Expression of NY-ESO-1 is limited to testis in healthy subjects,
however, it is often expressed de novo in HCC and other cancers
such as melanoma, ovarian, and breast cancer, with no apparent1 vol. 54 j 830–834 831
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gender bias. NY-ESO-1 is one of the most immunogenic TAAs
known to date, with several identiﬁed epitopes currently being
tested as potential vaccine candidates for cancers other than
HCC. By using different approaches, three groups reported NY-
ESO-1-speciﬁc CD8+ T cell responses in the peripheral blood of
HCC patients to an epitope that had already been identiﬁed in
melanoma patients [15–17] (Table 1). None of the observed T cell
responses were, however, detectable ex vivo and required several
weeks of in vitro lymphocyte expansion, suggesting a relatively
low frequency of these cells in the circulation.
SSX-2
SSX-2 is another cancer-testis antigen that has been recently
demonstrated to be over-expressed in HCC patients. By using a
CD8 T cell epitope that had been previously identiﬁed in mela-
noma patients, two groups detected CD8+ T cell responses in a
small fraction of HCC patients after in vitro expansion of PBMCs
and TILs [15,18] (Table 1).
Melanoma antigen gene-A (MAGE-A)
Antigens of the MAGE-A family were originally characterized in
melanoma, but they are also widely expressed in other tumours
such as breast carcinoma, glioma, colorectal carcinoma, and
HCC. Zerbini et al. demonstrated in vitro induction of CD8+ T cell
responses against previously identiﬁed MAGE-A1 and MAGE-A3
epitopes in tumour-inﬁltrating but not peripheral blood lympho-
cytes derived from HCC patients [19] (Table 1). Similarly, CD8+ T
cell responses against MAGE-A10 epitope have also been
described by Bricard et al. [18].
Telomerase reverse transcriptase (TERT)
TERT is a catalytic enzyme required for telomere elongation; its
expression correlates with telomerase activity. Tumours must
retain the length of their telomeres and telomerase helps them to
do so by maintaining telomeric ends of linear chromosomes and
protecting them from degradation. It is, therefore, not surprising
that telomerase has been reported to be activated in up to 85% of
all human cancers, including HCC, whereas TERT has been pro-
posed as a universal TAA for cancer immunotherapy. Interestingly,
Mizukoshi and colleagues reported ex vivomeasurable weak CD8+
T cell responses to six TRET epitopes in the peripheral blood of HCC
patients [20] (Table 1).
In summary, these studies show that although TAA-speciﬁc T
cells are detectable in patients with HCC, the frequency of these
responses is low overall and in vitro stimulation is often required
for their detection.Mechanisms responsible for inefﬁcient T cell responses
Several mechanisms could contribute to the weak and often inef-
ﬁcient TAA-speciﬁc CD8+ T cell responses in HCC patients (sum-
marized in Fig. 1).
Regulatory T cells (Tregs)
Tregs are the best characterized suppressor cells and have been
shown to suppress tumour immunity in numerous studies. In
HCC patients, Alexander and co-workers reported increased num-832 Journal of Hepatology 201bers of CD4+CD25+ Tregs in TILs, compared to distant tumour
tissue [21]. These ﬁndings were reinforced by the group of
Korangy and Greten who also reported increased frequencies of
CD4+CD25+ Tregs in TILs and PBMCs of HCC patients [22]. When
activated with CD3 and CD28 antibodies, these Tregs were found
to produce the immunosuppressive cytokine IL-10. Subsequently,
increased Tregs in TILs and PBMCs were shown to express Foxp3
and to inhibit CD3/CD28 stimulated CD8+ T cell proliferation,
activation, and production of granzymes and perforin [23]. These
combined results suggest that Tregs play a major role in the inhi-
bition of tumour-speciﬁc T cell responses in HCC. Further, this is
supported by the ﬁnding that depletion of Tregs resulted in the
emergence of tumour-speciﬁc CD4+ T cell responses in six out
of 16 HCC patients [24]. However, antigen-speciﬁcity of Tregs,
their functional and phenotypical proﬁles, as well as mechanisms
of suppression remain to be characterized in more detail.
Myeloid-derived suppressor cells (MDSCs)
MDSCs comprise a mixture of monocytes/macrophages, granulo-
cytes, and dendritic cells (DCs) at different stages of differentia-
tion. In patients with HCC, blood MDSCs have recently been
shown to induce Foxp3 and IL-10 expression in CD4+ T cells via
arginase activity [25]. There is currently no speciﬁc drug or anti-
body available that selectively targets MDSCs. Since inhibition of
arginase activity can cause side effects, due to the critical role of
this enzyme in the urea cycle, it will be important to identify
additional speciﬁc markers to target these cells.
Impairment of TAA processing and presentation
Several studies have shown that expression of HLA class I mole-
cules and B7 costimulatory molecules is downregulated in HCC
tissue [26] and HCC cell lines [27,28]. Such downregulation is
likely to lead to impaired processing of TAAs. Moreover, it has
been shown that circulating myeloid DCs in HCC patients were
decreased in numbers and had reduced cytokine production
[29], raising the possibility that TAA presentation by DCs may
also be impaired. Further work is required to determine the
extent and mechanisms of such impairment.
Inhibitory receptors
Many human cancers express PD-L1, the ligand for the inhibitory
receptor programmed cell death-1 (PD-1). Tumour-associated
PD-L1 has been shown to induce apoptosis of effector T cells
and is thought to contribute to immune evasion by cancers. In
HCC, tumour inﬁltrating CD8+ T cells are characterized by an
increase in PD-1 expression [30]. Interestingly, intratumoural
Kupffer cells have been shown to up-regulate PD-L1 and decrease
the effector function of PD-1-expressing CD8+ T cells in HCC
patients [31,32]. It should be noted that cells with a MDSC phe-
notype also up-regulated PD-L1 in these studies and exerted a
similar inhibitory effect on T cell activation, raising the possibility
of MDSC-mediated T cell suppression. Together these data sug-
gest that the inhibition of PD-1 may be a potential strategy in
the boosting of HCC-speciﬁc immunity. It will be important to
determine whether similar ﬁndings may be observed for other
important inhibitory receptors such as, for instance, CTLA-4,
BTLA, or Tim-3, and whether co-expression of these inhibitory
receptors is present in HCC, as has been described in other
tumour models [33,34].1 vol. 54 j 830–834
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Fig. 1. Multiple mechanisms may limit TAA-speciﬁc CD8+ T cell responses in HCC. Failure of TAA processing and presentation; insufﬁcient levels of CD4 help;
suppression of both CD4+ and CD8+ T cells by Tregs; negative regulation by PD-1/PD-L1 pathway.
JOURNAL OF HEPATOLOGYLack of CD4+ T cell responses
It is known that a lack of CD4+ T cell help may lead to CD8+ T cell
exhaustion. In fact, in HCC, AFP-speciﬁc CD4+ T cell responseswere
only present in patients with early stage disease and became
exhausted as the disease progressed [35]. Thus, for the activation
of fully functional cytotoxic T lymphocytes it will be important to
identify TAA-derived CD4 T helper cell epitopes and include them
in a vaccine along with CD8 T cell epitopes.
It is thus clear that the mechanisms underlying weak tumour-
speciﬁc T cell responses are complex, and their further in-depth
exploration is required for successful vaccine development. How-
ever, a few vaccination approaches have already been tested,
resulting in the generation of modest TAA-directed T cell
responses in HCC patients that will be summarized in the follow-
ing section.
Vaccine strategies
The group of Butterﬁeld and Economouwas the ﬁrst to conduct an
HCC vaccine clinical trial [12]. In this phase I trial, six HLA-A0201+
patients were immunized with AFP CD8 T cell epitopes, resulting
in the generation of measurable AFP-speciﬁc T cell responses in
the peripheral blood. In the consecutive phase I/II trial, the
authors attempted to further enhance these responses by loading
autologous DCs with AFP epitopes and administering them to 10
HLA-A0201+ patients [36]. This treatment, however, resulted only
in transient CD8+ T cell responses, possibly caused by the lack of
CD4 help. To overcome this limitation, a subsequent clinical trialJournal of Hepatology 201by the group of Adams used DCs pulsed with a lysate of the hepa-
toblastoma cell line HepG2 before transfusion into 35 HCC
patients with diverse HLA types [37]. Such an approach of using
apoptotic tumour cells as a source of multivalent antigens appears
to be ideal at the moment due to poor characterization of HCC
TAAs, and should allow the activation of both CD8+ and CD4+ T
cells. Indeed, the authors reported functional IFN-c-producing T
cells to vaccine and/or AFP in ﬁve patients, disease stabilization
for 6–16 months in six patients and reductions in serum AFP lev-
els in three patients. These positive results suggest that further
improvement of DC-based vaccination strategies, such as the
use of multiple TAA epitopes stimulating both CD8+ and CD4+ T
cells, may translate in more effective clinical results.
Perspectives for immunotherapy
Although the above-described vaccine approaches yielded the
most successful outcomes observed in T cell-based HCC immuno-
therapies so far, the achieved tumour-speciﬁc T cell responses
were often not robust enough to induce clinical responses. In
addition to HCC vaccines still being in early development, the
observed modest clinical efﬁcacy may be explained by the strong
tolerogenic environment at the tumour site and different tumour
suppressive mechanisms described above. Clearly, treatment
strategies combining blockade of immunoregulatory cell types
such as Tregs and MDSCs and of inhibitory receptors, with vac-
cine-induced activation of TAA-speciﬁc T cells may be necessary
to achieve the most effective therapeutic anti-tumour activity in
HCC. Also, a combination with conventional HCC treatments, such1 vol. 54 j 830–834 833
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as transarterial embolization or local tumour ablation may
increase HCC immunogenicity and unmask TAA-speciﬁc T cell
responses [38].
In conclusion, tremendous progress has been made in the ﬁeld
of immunotherapies for HCC in recent years. However, the reper-
toire of HLA class I and class II presented TAA-speciﬁc T cell epi-
topes needs to be expanded, and the mechanisms of T cell failure
require further investigation before immunotherapy of HCC can
successfully enter the clinical stage.
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